Lista de obras -

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

scientific article published in 2022

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

artículo científico publicado en 2016

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

artículo científico publicado en 2022

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women

artículo científico publicado en 2014

Benchmarks for Academic Oncology Faculty

scientific article published on 30 September 2020

Borderline estrogen receptor-positive breast cancers in black and white women

artículo científico publicado en 2019

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

artículo científico publicado en 2011

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

artículo científico publicado en 2017

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

scientific article published on 29 July 2021

Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab

scientific article published on 25 June 2020

Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer

artículo científico publicado en 2020

Defining breast cancer intrinsic subtypes by quantitative receptor expression

artículo científico publicado en 2015

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer

artículo científico publicado en 2014

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16<sup>INK4a</sup></i>

scientific article published on 18 December 2020

Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer

artículo científico publicado en 2017

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

artículo científico publicado en 2021

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

artículo científico publicado en 2011

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

artículo científico publicado en 2021

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

scientific article published on 25 June 2018

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

artículo científico publicado en 2013

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

artículo científico publicado en 2014

Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.

artículo científico publicado en 2016

Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer

artículo científico publicado en 2020

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

artículo científico publicado en 2016

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

scientific article published on 14 December 2018

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

scientific article published on 15 May 2019

Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer

artículo científico publicado en 2020

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

artículo científico publicado en 2015

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

artículo científico publicado en 2019

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

artículo científico publicado en 2014

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

artículo científico publicado en 2020

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

artículo científico publicado en 2022

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

artículo científico publicado en 2019

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

artículo científico publicado en 2019

Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review

artículo científico publicado en 2017

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

artículo científico publicado en 2017

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

artículo científico publicado en 2019

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

artículo científico publicado en 2020

Lista de obras de

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women

Benchmarks for Academic Oncology Faculty

Borderline estrogen receptor-positive breast cancers in black and white women

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab

Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer

Defining breast cancer intrinsic subtypes by quantitative receptor expression

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16<sup>INK4a</sup></i>

Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.

Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?